Author

Livio Trentin

Universit

Biography

Livio Trentin is a well-known researcher working in Department of Medicine, Hematology and Clinical Immunology Unit, University of Padua, Italy and has extended valuable service for many years and has been a recipient of many awards and grants.  
Title
Cited by
Year
BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib
S Bonfiglio, LA Sutton, V Ljungström, A Capasso, T Pandzic, S Weström, ...Blood Advances, bloodadvances. 20220021, 2023202
8
2023
Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV
P Zappasodi, C Cattaneo, V Valeria Ferretti, R Mina, A José María Ferreri, ...Hematological Oncology 40 (), 846-86, 2022202
5
2022
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study
L Pagano, M Criscuolo, A Broccoli, A Piciocchi, M Varettoni, E Galli, ...Blood Cancer Journal 12 (7), 109, 2022202
4
2022
A retrospective study on the efficacy of subcutaneous immunoglobulin as compared to intravenous formulation in patients with chronic lymphocytic leukemia and secondary antibody …
A Visentin, MC Molinari, S Pravato, A Cellini, F Angotzi, CA Cavaretta, ...Current Oncology 30 (1), 27-283, 2022202
4
2022
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: a real-life CLL campus study
A Visentin, FR Mauro, G Catania, A Fresa, C Vitale, A Sanna, V Mattiello, ...Frontiers in Oncology 12, 103313, 2022202
4
2022
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
M Gotti, R Sciarra, A Pulsoni, F Merli, S Luminari, C Zerbi, L Trentin, A Re, ...HemaSphere 7 (4), 20220
3
2023
CK1α/RUNX2 axis in the bone marrow microenvironment: a novel therapeutic target in multiple myeloma
A Fregnani, L Saggin, K Gianesin, L Quotti Tubi, M Carraro, G Barilà, ...Cancers 14 (17), 417, 2022202
3
2022
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
A Fresa, F Autore, A Piciocchi, G Catania, A Visentin, A Tomasso, ...Blood Advances 6 (13), 3875-3878, 0
2
2022
T021: Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2-RAFTING …
T01: Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET--RAFTING …A Gallamini, M Picardi, K Filonenko, M Gotti, JN Céspedes, A Rossi, ...HemaSphere 6, 10-11, 0
2
2022
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL
D Antic, N Milic, T Chatzikonstantinou, L Scarfò, V Otasevic, N Rajovic, ...Journal of hematology & oncology 15 (1), 1-13, 0
2
2022
A bone-based 3D scaffold as an in-vitro model of microenvironment–DLBCL lymphoma cell interaction
J Ceccato, M Piazza, M Pizzi, S Manni, F Piazza, I Caputo, F Cinetto, ...Frontiers in Oncology 2, 947823, 2022202
1
2022
Protein phosphorylation and redox status: an as yet elusive dyad in chronic lymphocytic leukemia
MA Pagano, F Frezzato, A Visentin, L Trentin, AM BrunatiCancers 4 (9), 488, 2022202
1
2022
SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort
SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐9 cohortM Merli, I Ferrarini, F Merli, A Busca, R Mina, B Falini, R Bruna, R Cairoli, ...Hematological Oncology 4 (), 28-38, 2023202
1
2023
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature
I Del Giudice, LV Cappelli, J Delgado, CU Niemann, MA Andersen, ...British journal of haematology, 2023202
1
2023
Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma
S Manni, M Pesavento, Z Spinello, L Saggin, A Arjomand, A Fregnani, ...Frontiers in Cell and Developmental Biology 0, 935023, 2022202
1
2022
Pre-exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents
FR Mauro, A Visentin, D Giannarelli, MC Molinari, G Proietti, M Petrella, ...British journal of haematology 20 (3), 564-567, 2023202
1
2023
Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia
M Kaufman, XJ Yan, W Li, EM Ghia, AW Langerak, LZ Rassenti, C Belessi, ...Frontiers in Oncology 2, 897280, 2022202
1
2022
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
JN Allan, IW Flinn, T Siddiqi, P Ghia, CS Tam, TJ Kipps, PM Barr, ...Clinical Cancer Research, OF-OF9, 2023202
1
2023

Referred From: https://scholar.google.com/citations?user=wtP2opQAAAAJ&hl=en

Cited by
Citations 16086
h-index 67
i10-index 249
Recommended Journals
Open Access Journals